CRISPR-Mediated Base Editing: Promises and Challenges for a Viable Oncotherapy Strategy
Human Gene Therapy · 2023-08 · 34 (15-16) · 669-681
DOI: 10.1089/hum.2023.045 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Human Gene Therapy, online erschienen am 16.08.2023. Verfasst von Lu Huang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Center, Sichuan Cancer Hospital and Institute, Affiliated Cancer …. Hauptthemen laut MEDLINE: Gene Editing, CRISPR-Cas Systems. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 123 Literaturangaben.
Abstract (Originalsprache)
Base editing technology, developed from the CRISPR/Cas9 system, is able to efficiently implement single-base substitutions at specific DNA or RNA sites without generating double-strand breaks with precision and efficiency. Point mutations account for 58% of disease-causing genetic mutations in humans, and single nucleotide variants are an important cause of tumorigenesis, and the advent of base editors offers new hope for the study or treatment of such diseases. Although it has some limitations, base editors have been continuously improved in terms of editing efficiency, specificity, and product purity since their development. In this review, we examine the main base editing technologies and discuss their applications and prospects in tumor research and therapy, as well as elaborate on their mode of delivery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Center, Sichuan Cancer Hospital and Institute, Affiliated Cancer Hospital of University of Electronic Science and Technology of China,…
- Personalized Drug Therapy Key Laboratory of Sichuan Province, Chengdu, China.
- Department of Traditional Chinese Medicine Surgery, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, China.
- Department of Gynecology and Obstetrics, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, China.
ORCID-Profile: Hongtao Xiao
Zitieren
APA
Huang, L., Yang, C., Chen, Y., Deng, H., Liao, Z., & Xiao, H. (2023). CRISPR-Mediated Base Editing: Promises and Challenges for a Viable Oncotherapy Strategy. Human Gene Therapy, 34(15-16), 669-681. https://doi.org/10.1089/hum.2023.045
Vancouver
Huang L, Yang C, Chen Y, Deng H, Liao Z, Xiao H. CRISPR-Mediated Base Editing: Promises and Challenges for a Viable Oncotherapy Strategy. Human Gene Therapy. 2023;34(15-16):669-681. doi:10.1089/hum.2023.045
BibTeX
@article{Huang2023,
author = {Huang, Lu and Yang, Chao and Chen, Yan and Deng, Han and Liao, Zhi and Xiao, Hongtao},
title = {CRISPR-Mediated Base Editing: Promises and Challenges for a Viable Oncotherapy Strategy},
journal = {Human Gene Therapy},
year = {2023},
volume = {34},
number = {15-16},
pages = {669--681},
doi = {10.1089/hum.2023.045}
}
EUVIMED